Skip to main content
. Author manuscript; available in PMC: 2015 Feb 19.
Published in final edited form as: Nat Genet. 2014 Mar 23;46(5):427–429. doi: 10.1038/ng.2928

Table 1. SMARCA4 mutations identified in germline and tumor DNA from SCCOHT cases.

Sample Age at diagnosis (years) Sequencing analysis performed SMARCA4 mutation in germline DNA SMARCA4 mutation in tumor DNA (total predicted SNVs)b Predicted protein alteration SMARCA4 IHC
SCCO-002a 26 Exome None None (2) None Negative
SCCO-008 9 Exome c.2935C>T NA p.Arg979* NA
SCCO-010 6 Exome None NA None Positive
SCCO-017 10 Exome c.722_735delGTCCCGGCCCGGCA NA p.Gly241fs Negative
SCCO-012 21 Exome NA None None Negative
SCCO-014 33 Exome NA c.[2001delG(;) 3481delC] p.Glu667fs
p.Leu1161fs
NA
SCCO-015 27 Exome NA c.3565C>T p.Arg1189* NA
DAH23 30 Exome NA c.2438+1_2438+2insTGA Splice-site mutation Negative
DAH456a 39 Exome None None (5) None Positive
DAH457 23 Exome NA c.3277C>T p.Arg1093* NA
DG1006a 34 Whole genome None c.[2855delA(;) 4771_4774delAGCG] (19) p.Glu952fs
p.Ser1591fs
Negative
DG1219a 37 Whole genome None c.3168+1G>A (12) Splice-site mutation Negative
BIN-67 Tumor cell line Whole genome NA c.[2438+1G>A(;) 2439-2A>T] 2 splice-site mutations Negative

NA, sample not available; IHC, immunohistochemistry.

a

Cases with a sequenced tumor-normal pair.

b

The number of total single-nucleotide variants (SNVs) is indicated only for tumors with a matching normal sample.